Business
Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements
Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 CARLSBAD, Calif., May 02, 2022 (GLOBE
About this update from Palisade Bio, Inc.
[{"type":"text","content":"Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022\nCARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline advancements. “The positive data we have amassed continues to support our development strategy and provides us with confidence as we advance our lead program into a Phase 3 study this quarter. Each day that a patient remains in the hospital can cost upwards of approximately $2,400, representing a significant burden on the cost of healthcare. We believe, if approved, LB1148 will protect gastrointestinal integrity and accelerate the return of postoperative GI function, providing hospitals with a potentially safe solution to accelerate patient discharge. Additionally, LB1148 has the potential to reduce abdominal adhesions – a problem that can cause an alarming number of post-surgery complications. With our data in hand, we have aligned on a strategy for LB1148 to transform the current standard of care which will allow us to unlock significant value for our shareholders,” commented Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio. Clinical Program Update LB1148: oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery LB1148 is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with potential to both reduce abdominal adhesions and help restore bowel function following surgery. The therapy is being developed for administration prior to major surgeries that are at risk of disrupting the intestinal epithelial barrier. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to the return of normal GI function, and shorten the duration of costly post-surgery hospital stays. Postoperative Return of Bowel Function: GI Surgery ...